Related Experiment Video
Updated: Apr 28, 2026
09:46
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
Published on: September 21, 2021
5.0K
Contemporary treatment options for relapsing-remitting multiple sclerosis.
S Salhofer-Polanyi1, F Leutmezer2
1Department of Neurology, Medical University of Vienna, Vienna, Austria.
Drugs of Today (Barcelona, Spain : 1998)
|June 12, 2014
Summary
Recent advancements in multiple sclerosis (MS) treatment offer improved efficacy for managing this autoimmune neurological disease. This review covers current therapies and emerging drugs for relapsing-remitting MS, addressing safety and tolerability.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Multiple sclerosis (MS) is a central nervous system autoimmune disorder with neuroinflammatory and neurodegenerative components.
- MS often leads to progressive neurological disability, historically challenging to halt with available treatments.
Purpose of the Study:
- To review the efficacy, safety, and tolerability of currently approved drugs for relapsing-remitting MS.
- To provide an update on novel therapies in late-stage clinical trials for MS management.
Main Methods:
- Literature review of clinical trial data for MS therapeutics.
- Analysis of efficacy, safety, and tolerability profiles of licensed and investigational MS drugs.
Main Results:
- Significant progress in MS treatment efficacy has been achieved with newly approved medications.
- Several promising new drugs are advancing through phase III clinical trials, indicating future therapeutic options.
Conclusions:
- Current MS treatments show improved efficacy, with ongoing development of novel therapies.
- The therapeutic landscape for relapsing-remitting MS is rapidly evolving, offering better patient outcomes.
Keywords:
AlemtuzumabDimethyl fumarateFingolimodMultiple sclerosisRelapsing-remitting multiple sclerosisTeriflunomideMore Related Videos
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
19
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
19
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:28Drug Therapy
446
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
446
01:20Myasthenia Gravis: Overview and Treatment
3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
01:26Psychosis: Goals of Pharmacotherapy
699
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
699
01:30Electroconvulsive Therapy
2.6K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.6K